Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population

Wu, Bingcao; Muser, Erik; Teeple, Amanda; Pericone, Christopher D.; Feldman, Steven R.

doi:10.1080/09546634.2019.1687828

Cited by 16 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in medical coverage/usage in nationalized health systems vs. under commercial insurance in the United States (US), as well as the effect of the availability of additional biologics (which has been shown to increase rates of switching) [31] in the present, more recent study, likely contributed to this finding. In a recent assessment of US insurance claims for a period immediately prior to that assessed in the present report, the 1-year persistence based on a 90-day gap was 59.4% and 60.5% for secukinumab and ustekinumab, respectively [32], which is comparable to the * 64% seen for ixekizumab and guselkumab herein. A recent study based on patients in the large North American Corrona Psoriasis Registry compared persistence (based on a 60-day allowable gap) between ixekizumab, non-ixekizumab IL-17 inhibitors, and TNF inhibitors [8].…”

Section: Gus Guselkumabsupporting

confidence: 68%

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab

Blauvelt

Burge

Gallo

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Persistence and adherence to psoriasis treatments reflect overall drug effectiveness, tolerability, and convenience. Limited data are available on the treatment patterns of ixekizumab, an interleukin (IL)-17A antagonist, vs. guselkumab, an IL-23 inhibitor. Our objective was to evaluate real-life psoriasis drug treatment patterns with ixekizumab vs. guselkumab. Methods: This retrospective observational study used United States insurance claims data from IBM Watson MarketScan Databases to analyze treatment patterns (including adherence, persistence, time on monotherapy, switching, and use of concomitant medications)for patients with 1 year, C 6 months, and up to 30 months of follow-up. Outcomes were compared between ixekizumab and guselkumab on the balanced sample after applying inverse probability of treatment weighting (IPTW). Results: Data for 1414 eligible patients (ixekizumab, N = 674 and guselkumab, N = 740) were assessed. Over the 1-year follow-up, adherence was greater for ixekizumab vs. guselkumab when evaluated by proportion of days covered C 80% [odds ratio (OR) 1.77 (95% confidence interval, 1.41, 2.21), p \ 0.001] and by medication possession ratio C 80% [OR = 1.92 (1.54, 2.38), p \ 0.001]. Persistence was longer for ixekizumab vs. guselkumab with a 60-day allowable gap [non-persistence hazard ratio (HR) (95% confidence interval): 0.80 (0.69, 0.93), p = 0.005], but there were no differences with a 90-day allowable gap [HR = 0.98 (0.83, 1.17), p = 0.850]. Results assessed in patients with C 6 months follow-up confirmed these findings. This retrospective analysis of a United States claims database used prescription refill data to estimate persistence/adherence. Conclusions: Based on real-world evidence using claims data, patients with psoriasis treated with ixekizumab had a greater adherence to and an equal or greater persistence with therapy vs. patients treated with guselkumab.

show abstract

Section: Gus Guselkumabsupporting

confidence: 68%

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab

Blauvelt

Burge

Gallo

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…This is in the upper range of previously published results ( Table VII ), which vary widely due to presumed differences in the methodical approaches used by the groups reporting them. For instance, lower 12-month survival rates were detected in insurance claims databases from France (30.7%) and the United States (2.6%) 24 , 36 and in the Slovenian psoriasis registry (20.0%). 13 However, rates similar to ours were seen in retrospective observational studies from Spain (54.9%) 25 and Japan (53.4%), 28 although the apremilast-treated cohorts in most of those studies were smaller than ours.…”

Section: Discussionmentioning

confidence: 99%

“…[21][22][23] Most biologics have similar overall drug survival rates (per drug within a certain range), but the 12-month survival rates of apremilast range widely by study, from 2.6% to 55.4%. 24,25 Decreased biologic drug survival is associated with female sex, previous biologic exposure, and obesity. 26 For most biologics, metabolic conditions (ie, hypertension, diabetes, and metabolic syndrome and its associated comorbidities) increase the risk of treatment discontinuation, although this was not the case for apremilast in a previous study.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

et al. 2021

View full text Add to dashboard Cite

Background Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction. Methods This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry. Results Data from 367 patients were eligible for analysis. The 12-month drug survival rate associated with apremilast (ie, the proportion of patients on the drug) was 57.3% and decreased significantly in patients younger than 40 years (relative hazard ratio = 1.49, P = .007918). Sex; concomitant arthritis; previous biologic therapy; obesity; and palmoplantar, scalp, nail, and intertriginous involvement did not significantly affect drug survival. At 12 months, the response rates in patients receiving apremilast per protocol with a PASI of 50, 75, 90, and 100 were 80.0%, 56.4%, 38.2%, and 22.7%, respectively. Limitations Inclusion of a substantial number of patients with no record of absolute PASI at study entry and lack of PASI reduction follow-up data of 103 patients (28.1%) after starting apremilast treatment. Conclusion Apremilast is a robust antipsoriatic drug for which the drug survival is not strongly influenced by most patient- or disease-related factors except age. Drug survival is significantly shorter in patients younger than 40 years.

show abstract

“…Сучасна терапія псоріазу полягає у стримуванні проявів хвороби, вибір тактики лікування залежить від ступеню важкості перебігу [6,14,20]. Європейський консенсус експертів лікарів визначив показник ефективності лікування та розробив алгоритм визначення лікувальної тактики, де зазначено, що успішною є відповідь на лікування псоріатичних висипань, якщо їх поширеність або площа зменшилася до 75% -площа активного запального процесу бляшки (індексу ураження шкіри й тяжкості псоріатичного процесу (PASI) -(PASI 75) від вихідного рівня або 50% зниження PASI (PASI 50) та показник дерматологічного індексу якості життя (DLQI) <5 балів [4,11].…”

Section: вступunclassified

Psoriasis therapy: problems and prospects

Melnyk¹,

Bondar²,

Melnyk³

et al. 2020

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Modern therapy of psoriasis is to contain the manifestations of the disease, the choice of treatment tactics depends on the severity of the course. However, the effectiveness of standardized complex therapy remains rather low and the results of treatment are unpredictable, which requires further study of ways to increase the effectiveness of psoriasis therapy. Aim – to evaluate the effectiveness of standard psoriasis therapy. An analysis of the effectiveness of standard therapy for psoriasis was carried out in 30 patients who were under the supervision of a dermatologist at the Vinnitsa Regional Clinical Dermato-Venereal Dispensary in 2019–2020. In addition to general clinical research methods, the patients were evaluated for the skin lesion index and the severity of the psoriatic process (PASI) and the quality of life was assessed – the dermatological index of quality of life (DLQI). Statistical processing of the study data was performed using the program Statistica® (StatSoft, Tulsa Oklahoma), using the Wilcoxon test, the difference between the mean m at p<0.05 was considered probable. The results obtained showed the existence of an empirical approach to therapy and the choice of topical and systemic drugs. The low efficiency of the used therapy tactics was also found, as indicated by the insignificant dynamics of the PASI and DLQI indicators. The PASI indicator decreased from 11.6 to 7.6 (p≥0.05), and the DLQI indicator decreased from 14 to 10 points (p≥0.05). In general, the indicators of the group corresponded to the average severity of the course of the disease when it is necessary to give preference to complex topical therapy with the addition of systemic drugs in some cases. However, the question of a rational combination of drugs that can enhance the basic therapy remains open. Thus, modern therapy of patients with psoriasis is insufficiently effective in controlling both the disease itself and in relation to the impact on the quality of life of patients. Insufficient effectiveness of existing treatment combinations requires further search for promising drugs.

show abstract

Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population

Cited by 16 publications

References 21 publications

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis

Psoriasis therapy: problems and prospects

Contact Info

Product

Resources

About